Gastric Cancer Connect
  • Saved

1mo
The emerging implications of GLP-1 receptor agonists in radiation therapy. - PubMed

The emerging implications of GLP-1 receptor agonists in radiation therapy. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41776829

Examine how GLP-1 receptor agonists impact radiation therapy planning, emphasizing adaptive techniques and formal guidelines in oncology.


GLP-1 RAs may influence radiation therapy planning due to weight loss, delayed gastric emptying, and side effects. Adaptive techniques and consensus guidelines are needed.

  • Saved

1mo

In advanced gastric cancer, which molecular finding most significantly shapes your treatment approach?

  • Saved

2mo
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements. - PubMed

Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41841439

Experts reached consensus in the first Delphi round on gastric cancer peritoneal metastasis management, except systemic treatment, highlighting research needs.


The IGCA developed 13 consensus statements for gastric cancer peritoneal metastasis management in the first Delphi round, highlighting research needs for systemic treatment.

  • Saved

2mo
Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction. - PubMed

Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41920914

Rectal and nasogastric encorafenib with FOLFOX+EC is under study for BRAF V600E-mutant rectal cancer; initial findings suggest manageable short-term safety.


Rectal and nasogastric encorafenib with FOLFOX+EC is being studied for BRAF V600E-mutant rectal cancer; initial findings suggest manageable short-term safety.

  • Saved

1yr
Advancing Oncology Care: First-Line Innovations and Supportive Strategies from ASCO 2025

At the 2025 ASCO Annual Meeting, Dr. Eric Winer, Director of Yale Cancer Center and President of Smilow Cancer Hospital, presented data supporting the use of trastuzumab deruxtecan in the first-line setting for HER2-positive metastatic breast cancer. The drug demonstrated a median progression-free survival approaching 3.5 years, significantly outperforming standard chemotherapy and antibody combinations. Dr. Winer also highlighted a pivotal colon cancer study in which structured exercise interventions were associated with reduced recurrence and improved overall survival, underscoring the growing role of supportive care in oncology.

Dr. Sara Tolaney of Dana-Farber Cancer Institute discussed findings from the ASCENT-04 trial, which showed that sacituzumab govitecan combined with pembrolizumab improved progression-free survival (11.2 vs. 7.8 months; hazard ratio [HR] 0.65) compared to chemotherapy plus pembrolizumab in treatment-naive, PD-L1-positive metastatic triple-negative breast cancer patients. These findings highlight a promising potential frontline strategy for this aggressive disease subtype.